Compare NVMI & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVMI | VTRS |
|---|---|---|
| Founded | 1993 | 1961 |
| Country | Israel | United States |
| Employees | N/A | 30000 |
| Industry | Electronic Components | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.0B | 18.7B |
| IPO Year | 2001 | 2019 |
| Metric | NVMI | VTRS |
|---|---|---|
| Price | $500.45 | $16.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $431.88 | $13.50 |
| AVG Volume (30 Days) | 483.1K | ★ 9.0M |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 3.21% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $14,299,900,000.00 |
| Revenue This Year | $20.94 | $4.41 |
| Revenue Next Year | $19.53 | $1.96 |
| P/E Ratio | ★ $56.79 | $107.90 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $232.73 | $8.63 |
| 52 Week High | $615.99 | $17.53 |
| Indicator | NVMI | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 46.18 | 55.14 |
| Support Level | $474.03 | $16.02 |
| Resistance Level | $549.70 | $16.54 |
| Average True Range (ATR) | 27.57 | 0.46 |
| MACD | -6.49 | 0.02 |
| Stochastic Oscillator | 18.00 | 80.21 |
Nova Ltd is a provider of metrology and process control solutions used in semiconductor manufacturing. The company provides high-performance metrology solutions across the semiconductor fabrication lifecycle and develops differentiated inline metrology solutions deployed by a broad range of customers, including integrated circuit manufacturers. Its portfolio combines high-precision hardware and software, enabling customers to improve device performance, enhance yields, and accelerate time to market. Its products include Dimensional Metrology, Materials Metrology, Chemical Metrology, and Software Solutions. The company operates in China, Taiwan, R.O.C., the United States and other regions, with maximum revenue coming from China.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.